HOXD13 and lung cancer: We found that the serum sPD-1 from NSCLC patients is significantly decreased compared with that of tumor-free individuals, especially in phase I of NSCLC patients, suggesting that sPD-1 can serve as a potential marker for the early diagnosis of lung cancer.